此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Sodium and Milk Fortification Evaluation of Body Composition Among Very Preterm Infants (SAFE)

2026年5月23日 更新者:Katie Strobel、University of Washington
The goal of the trial is to learn if targeted sodium supplementation (including blood and urine sodium testing) versus standard milk fortification (including blood sodium testing) improves growth and body composition in very preterm infants?

研究概览

详细说明

Very preterm infants (born <32 weeks gestational age) are at high risk for postnatal growth faltering, which is associated with adverse neurodevelopmental outcomes. Despite routine use of enriched human milk fortification in the NICU, many infants fail to achieve adequate somatic and lean mass growth. Sodium depletion has been identified as a potentially modifiable contributor to this problem: renal tubular immaturity in preterm infants results in obligate urinary sodium wasting. Total body sodium depletion has been associated with poor growth in infants and poor muscle mass development in animal studies.

Current NICU practice relies primarily on serum sodium to guide supplementation; however, serum sodium is a late and insensitive marker of total body sodium depletion. Urine sodium is a more sensitive indicator of sodium balance and may identify depletion before serum levels fall. Gestational-age-specific urine sodium thresholds to guide supplementation have recently been proposed (Stalter et al., 2025), but have evaluated body composition in a prospective randomized trial.

This trial tests whether a structured, urine sodium-guided supplementation protocol based on every other week urine and serum sodium monitoring improves anthropometric growth and lean mass accrual compared to standard enriched fortification alone. The intervention runs from day of life 14 through 36 weeks postmenstrual age, with tapering through 38 weeks PMA.

Body composition assessment incorporates two complementary modalities: serial point-of-care ultrasound (POCUS) of the biceps, rectus femoris, and subcutaneous fat for longitudinal lean and fat mass tracking, and Air Displacement Plethysmography (PeaPod) at 36 weeks postmenstrual age or discharge for criterion-standard whole-body composition. Fat mass, fat-free mass, and body fat percentage will be referenced against the Norris et al. preterm normative curves.

The trial uses an open-label design with block randomization stratified by gestational age. A Data Safety and Monitoring Board will conduct oversight and interim safety reviews.

研究类型

介入性

注册 (估计的)

150

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:John Feltner, MS
  • 电话号码:(206) 543-3200
  • 邮箱:jfeltner@uw.edu

学习地点

    • Ohio
      • Cincinnati、Ohio、美国、45221
        • 尚未招聘
        • University of Cincinnati
        • 接触:
    • Oregon
      • Portland、Oregon、美国、97239
        • 尚未招聘
        • Oregon Health & Science University
        • 接触:
    • Washington
      • Seattle、Washington、美国、98195
        • 招聘中
        • University of Washington
        • 接触:
          • Katie M Strobel, MD, MSCR
          • 电话号码:(206) 543-3200
          • 邮箱:kmstrob@uw.edu
        • 副研究员:
          • D Taylor Hendrixson, MD, MPH

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子

接受健康志愿者

不

描述

Inclusion Criteria:

  • Admitted to the University of Washington, Oregon Health and Sciences, or University of Cincinnati NICU at 14 days of age
  • Born between 24w0days and 31w6d
  • Achieved full enteral feeding

Exclusion Criteria:

  • Congenital or chromosomal anomalies affecting growth
  • Acute renal insufficiency (KDIGO stage 1 or higher)
  • Necrotizing enterocolitis (modified Bell's stage IIA or higher)
  • Anticipated NICU stay less than 30 days
  • Enrollment in a concurrent interventional study that may confound study outcomes

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Targeted sodium supplementation
Every two weeks serum sodium and urine sodium testing with sodium supplementation if indicated by algorithm. Milk fortification per growth metrics.
The investigators will utilize urine sodium testing every two weeks in conjunction with serum sodium testing to determine if sodium supplementation is indicated.
The investigators will use serum sodium testing to determine if sodium supplementation or adjustments to sodium supplementation need to be made.
The investigators will provide milk fortification using either a bovine-based or a human-milk-based fortifier (per unit protocol), based on growth trajectories.
有源比较器:Enriched Milk Fortification
Serum sodium testing every two weeks with sodium supplementation if indicated by clinical team. Milk fortification per growth metrics.
The investigators will use serum sodium testing to determine if sodium supplementation or adjustments to sodium supplementation need to be made.
The investigators will provide milk fortification using either a bovine-based or a human-milk-based fortifier (per unit protocol), based on growth trajectories.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Body composition by point-of-care ultrasound
大体时间:Enrollment to study completion, on average 4-10 weeks
Evaluate muscle and subcutaneous fat accretion from enrollment to 36 weeks posmtnestrual age. The study team will perform biceps and rectus femoris cross-sectional area measurements using point-of-care ultrasound every 2 weeks. We will perform arm and mid-thigh subcutaneous fat measurements using point-of-care ultrasound every 2 weeks.
Enrollment to study completion, on average 4-10 weeks

次要结果测量

结果测量
措施说明
大体时间
Body composition using air-displacement plethysmography
大体时间:At study completion, on average 4-10 weeks
We will conduct air-displacement plethysmography when the infant is off of oxygen at 36 weeks postmenstrual age or prior to discharge, whichever comes earlier.
At study completion, on average 4-10 weeks

其他结果措施

结果测量
措施说明
大体时间
Anthropometric growth
大体时间:Enrollment to study completion, on average 4-10 weeks
The clinical team measures weight, length, and head circumference z-scores weekly during hospitalization. The investigators will evaluate the change in z-score from birth to 36 weeks postmenstrual age
Enrollment to study completion, on average 4-10 weeks
Adverse outcomes
大体时间:Enrollment to hospital discharge, on average between 4 to 16 weeks
The study team will evaluate adverse outcome rates such as bronchopulmonary dysplasia, necrotizing enterocolitis, and all-cause mortality.
Enrollment to hospital discharge, on average between 4 to 16 weeks

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Katie Strobel, MD, MSCR、University of Washington

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年5月18日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2029年10月31日

研究注册日期

首次提交

2026年3月31日

首先提交符合 QC 标准的

2026年4月28日

首次发布 (实际的)

2026年5月1日

研究记录更新

最后更新发布 (实际的)

2026年5月28日

上次提交的符合 QC 标准的更新

2026年5月23日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

其他研究编号

  • STUDY00023657

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Once the study and planned analyses are complete, we will submit de-identified participant data to a public database such as Zenodo.

IPD 共享时间框架

We anticipate this data would be available October 2030 and would be available untl 2040.

IPD 共享支持信息类型

  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

是的

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅